Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
This is a 41.7% decrease from the number of companies inspected in the previous quarter, when 12 companies received 12 inspections.
Most of the companies inspected at the time were involved in the Biologics and Food and Cosmetics sectors. The second most common type of company inspected worked in the Drugs sector.
There were five companies in line with FDA regulations that do not need to adjust their management operations or regulatory/administrative actions. Two should take voluntary action to correct their management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
| Company Name | Area of Business | Inspection Date | Result |
|---|---|---|---|
| Daesang America, Inc. | Food and Cosmetics | 07/08/2024 | No Action Indicated (NAI) |
| De Matteis Food Corporation | Food and Cosmetics | 07/19/2024 | No Action Indicated (NAI) |
| Hackensack University Medical Center Blood Bank | Biologics | 09/17/2024 | No Action Indicated (NAI) |
| Micra Biotechnologies, Inc. | Drugs | 08/02/2024 | Voluntary Action Indicated (VAI) |
| North Hudson IVF Center for Fertility & Gynecology, P.C. | Biologics | 07/02/2024 | Voluntary Action Indicated (VAI) |
| Osem USA, Inc. | Food and Cosmetics | 07/15/2024 | No Action Indicated (NAI) |
| Stryker Spine | Biologics | 09/27/2024 | No Action Indicated (NAI) |
Alerts Sign-up